PNC Financial Services Group Inc. grew its stake in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 225.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,225 shares of the medical research company's stock after acquiring an additional 14,011 shares during the period. PNC Financial Services Group Inc.'s holdings in Bruker were worth $1,186,000 at the end of the most recent quarter.
A number of other large investors also recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC lifted its position in shares of Bruker by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company's stock worth $779,000 after buying an additional 177 shares during the last quarter. Arizona State Retirement System lifted its position in shares of Bruker by 0.7% in the 4th quarter. Arizona State Retirement System now owns 30,725 shares of the medical research company's stock worth $1,801,000 after buying an additional 222 shares during the last quarter. CIBC Asset Management Inc lifted its position in shares of Bruker by 5.6% in the 4th quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company's stock worth $248,000 after buying an additional 223 shares during the last quarter. UMB Bank n.a. lifted its position in shares of Bruker by 37.5% in the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock worth $53,000 after buying an additional 248 shares during the last quarter. Finally, Blue Trust Inc. lifted its position in shares of Bruker by 13.5% in the 4th quarter. Blue Trust Inc. now owns 2,164 shares of the medical research company's stock worth $127,000 after buying an additional 257 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
BRKR has been the topic of a number of recent research reports. UBS Group initiated coverage on shares of Bruker in a research report on Tuesday, December 10th. They issued a "neutral" rating and a $66.00 price target on the stock. The Goldman Sachs Group upgraded shares of Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price target on the stock in a research report on Thursday, December 5th. Stifel Nicolaus cut their price objective on shares of Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a research report on Friday, February 14th. Barclays cut their price objective on shares of Bruker from $69.00 to $65.00 and set an "overweight" rating on the stock in a research report on Monday, February 10th. Finally, Bank of America lifted their price objective on shares of Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a research report on Friday, December 13th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Bruker has an average rating of "Moderate Buy" and an average price target of $70.50.
Read Our Latest Research Report on BRKR
Bruker Price Performance
Shares of BRKR stock traded down $2.21 during midday trading on Thursday, reaching $44.47. 2,253,084 shares of the company were exchanged, compared to its average volume of 1,295,532. Bruker Co. has a 12 month low of $44.11 and a 12 month high of $94.86. The company has a market cap of $6.75 billion, a P/E ratio of 58.51, a PEG ratio of 2.16 and a beta of 1.18. The company's 50 day moving average price is $52.82 and its two-hundred day moving average price is $58.00. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60.
Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. On average, sell-side analysts expect that Bruker Co. will post 2.69 earnings per share for the current year.
Bruker Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Monday, March 17th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.45%. Bruker's dividend payout ratio (DPR) is 26.32%.
About Bruker
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Featured Stories
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
